Skip to content
value.today

Merus

2GH.F
$1.6 Blast known market cap, Jan 2024 — no current value
Compare
World rank
—
no current market cap
Revenue
—
annual
Net income
—
Employees
—

Merus in brief

Merus is a listed company in the Biotechnology industry, based in the Netherlands. Its last known market value was $1.6 B (January 2024); there is no current figure. Its shares trade under the symbol 2GH.F (Frankfurt).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Merus

Merus is a clinically advancing edge company targeted treatments to address the unmet needs of patients with various types of cancer. The headquarters is in Netherland.

Merus company annual revenue was 41 million USD and annual net income was -131 million USD for year ending December 2022.

Market cap history

$0 M$443 M$886 M$1.3 B$1.8 B20202021202220232024

World rank over time

▲ up 5,495 places since 2020
2020-01-01: #11909#11,90920202021-01-01: #11065#11,06520212022-01-07: #8381#8,38120222022-12-25: #10405#10,40520222023-07-30: #7567#7,56720232024-01-05: #6414#6,4142024

Rank in Netherlands: #78 (Jan 2020) · #80 (Jan 2021) · #61 (Jan 2022) · #67 (Dec 2022) · #51 (Jul 2023) · #45 (Jan 2024)

Where Merus operates: 1 country#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue.

Present: offices, subsidiaries, branches or revenue (1 country)Nothing on fileDots mark countries too small to see. Hover, tap or tab to a country for its figures.

Only the headquarters country is on file for Merus: no subsidiaries, branches, offices or country revenue elsewhere in the GLEIF register, its SEC filings or Wikidata.

Merus: countries of operation
CountryPresenceRevenue there
🇳🇱 NetherlandsHeadquarters—

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file; map outlines from Natural Earth. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

FDA drug approvals: Merus#

1 approved applications held, 1 of them new molecular entities; 1 approvals and 0 new uses in 2024.

Approvals held
1
New molecular entities
1
New uses approved
1
efficacy supplements
Generics
0
0 new drugs, 1 biologics
Merus: latest FDA approvals
ApprovedDrugKind
2026-05-08Bizengrinew useZenocutuzumab-Zbco · BLA761352 (SUPPL-10)Biologic (BLA)
2024-12-04Bizengrinew moleculeZenocutuzumab-Zbco · BLA761352Biologic (BLA)

Source: Drugs@FDA (openFDA). Approvals are listed under the application's current holder (MERUS N.V.), so they follow acquisitions

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Merus🇳🇱$1.6 B———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Jan 5, 2024 (last known)
Profile updated:
Nov 4, 2026

Figures from value.today research.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Merus? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Merus's ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Merus? Suggest a correction